Transfection of dendritic cells with in vitro-transcribed CMV RNA induces polyclonal CD8+- and CD4+-mediated CMV-specific T cell responses

被引:18
作者
Heine, A
Grünebach, F
Holderried, T
Appel, S
Weck, MM
Dörfel, D
Sinzger, C
Brossart, P
机构
[1] Univ Tubingen, Dept Hematol Oncol & Immunol, D-72076 Tubingen, Germany
[2] Univ Tubingen, Inst Med Virol & Epidemiol Viruskrankheiten, D-72076 Tubingen, Germany
关键词
RNA transfection; dendritic cells; CTL; immunotherapy; CMV;
D O I
10.1016/j.ymthe.2005.08.019
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Transfection of dendritic cells (DCs) with RNA was shown to be effective in the generation of antigen-specific T cells, probably due to the induction of a polyclonal T cell response directed against multiple antigens. To verify this assumption we used DCs, generated from cytomegalovirus (CMV)-negative or -positive donors, that were electroporated with in vitro-transcribed RNA (in vitro transcript, IVT) coding for the CMV pp65 antigen. We found that transfection of DCs with pp65 IVT induces an expansion of polyclonal CD8(+) T lymphocytes that recognize peptide antigens presented on different HLA molecules. These T lymphocytes are able to lyse DCs pulsed with pp65-derived peptides or transfected with the cognate IVT. Furthermore, this approach allowed the identification of immunodominant epitopes presented upon IVT transfection. Interestingly, transfection of DCs with pp65 IVT resulted in the induction of CD4(+)-specific T cells. Cotransfection of DCs with IVTs coding for the CMV antigens pp65 and IE1 elicited polyclonal T lymphocytes specific for peptides derived from both antigens. More importantly, cytotoxic T cells could be generated in two of three CMV-negative donors. Finally, functional CMV-specific autologous cytotoxic T lymphocytes were successfully generated from immunosuppressed patients after allogeneic hematopoietic stem cell transplantation.
引用
收藏
页码:280 / 288
页数:9
相关论文
共 35 条
[1]   DEVELOPMENT OF HIGH POTENCY UNIVERSAL DR-RESTRICTED HELPER EPITOPES BY MODIFICATION OF HIGH-AFFINITY DR-BLOCKING PEPTIDES [J].
ALEXANDER, J ;
SIDNEY, J ;
SOUTHWOOD, S ;
RUPPERT, J ;
OSEROFF, C ;
MAEWAL, A ;
SNOKE, K ;
SERRA, HM ;
KUBO, RT ;
SETTE, A ;
GREY, HM .
IMMUNITY, 1994, 1 (09) :751-761
[2]   Dendritic cells and the control of immunity [J].
Banchereau, J ;
Steinman, RM .
NATURE, 1998, 392 (6673) :245-252
[3]   HUMAN CYTOMEGALOVIRUS-SPECIFIC CYTO-TOXIC T-CELLS - RELATIVE FREQUENCY OF STAGE-SPECIFIC CTL RECOGNIZING THE 72-KD IMMEDIATE EARLY PROTEIN AND GLYCOPROTEIN-B EXPRESSED BY RECOMBINANT VACCINIA VIRUSES [J].
BORYSIEWICZ, LK ;
HICKLING, JK ;
GRAHAM, S ;
SINCLAIR, J ;
CRANAGE, MP ;
SMITH, GL ;
SISSONS, JGP .
JOURNAL OF EXPERIMENTAL MEDICINE, 1988, 168 (03) :919-931
[4]   Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies [J].
Brossart, P ;
Heinrich, KS ;
Stuhler, G ;
Behnke, L ;
Reichardt, VL ;
Stevanovic, S ;
Muhm, A ;
Rammensee, HG ;
Kanz, L ;
Brugger, W .
BLOOD, 1999, 93 (12) :4309-4317
[5]  
Brossart P, 1998, CANCER RES, V58, P732
[6]   Generation of functional human dendritic cells from adherent peripheral blood monocytes by CD40 ligation in the absence of granulocyte-macrophage colony-stimulating factor [J].
Brossart, P ;
Grünebach, F ;
Stuhler, G ;
Reichardt, VL ;
Möhle, R ;
Kanz, L ;
Brugger, WR .
BLOOD, 1998, 92 (11) :4238-4247
[7]   Processing and presentation of HLA class I and II epitopes by dendritic cells after transfection with in vitro-transcribed MUC1 RNA [J].
Dörfel, D ;
Appel, S ;
Grünebach, F ;
Weck, MM ;
Müller, MR ;
Heine, A ;
Brossart, P .
BLOOD, 2005, 105 (08) :3199-3205
[8]   CMV-specific immunotherapy [J].
Einsele, H ;
Hebart, H .
HUMAN IMMUNOLOGY, 2004, 65 (05) :558-564
[9]   Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy [J].
Einsele, H ;
Roosnek, E ;
Rufer, N ;
Sinzger, C ;
Riegler, S ;
Löffler, J ;
Grigoleit, U ;
Moris, A ;
Rammensee, HG ;
Kanz, L ;
Kleihauer, A ;
Frank, F ;
Jahn, G ;
Hebart, H .
BLOOD, 2002, 99 (11) :3916-3922
[10]   Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection [J].
Einsele, H ;
Hebart, H ;
Kauffman-Schneider, C ;
Sinzger, C ;
Jahn, G ;
Bader, P ;
Klingebiel, T ;
Dietz, K ;
Löffler, J ;
Bokemeyer, C ;
Müller, CA ;
Kanz, L .
BONE MARROW TRANSPLANTATION, 2000, 25 (07) :757-763